{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '51', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Extension Study in China', 'NOTE: As of Amendment 007-06, enrollment in the Extension Study in China has been', 'stopped; the planned enrollment goal of 120 participants was not reached.', 'Lenvatinib and matching placebo are removed from the extension study and it will proceed', 'identical to the global study as per this protocol amendment (eg, study endpoints, primary', 'and secondary objectives, study procedures), with the exception of an additional', 'supplemental statistical analysis plan (sSAP), which will provide details of analyses specific', 'to Chinese participants.', 'Specific procedures to be performed during the study, as well as their prescribed times and', 'associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure', 'are provided in Section 8.', '4.2', 'Scientific Rationale for Study Design', 'This Phase 3 study is being conducted to evaluate the efficacy and safety of pembrolizumab', 'in metastatic NSCLC when administered in combination with lenvatinib. Lenvatinib (20 mg', 'QD) will be evaluated in combination with the standard dose of pembrolizumab (200 mg', 'Q3W).', '4.2.1', 'Rationale for Enppoints', '4.2.1.1', 'Efficacy Enppoints', 'This study will use PFS based on RECIST 1.1 criteria, adjusted to follow a maximum of', '10 target lesions and a maximum of 5 target lesions per organ, as assessed by BICR as a', 'primary endpoint and OR as a secondary efficacy endpoint. PFS and OR are acceptable', 'measures of clinical benefit for a late-stage study that demonstrates superiority of a new', 'antineoplastic therapy, especially if the magnitude of the effect is large and the therapy has', 'an acceptable risk/benefit profile. The use of BICR and RECIST 1.1 to assess PFS and OR', 'are typically considered acceptable by regulatory authorities. Images will be read by a central', 'imaging vendor blinded to treatment assignment to minimize bias in the response', 'assessments. In addition, the final determination of radiologic progression will be based on', 'the central assessment of progression, rather than a local site investigator/radiology', 'assessment. Real time determination of radiologic progression as determined by central', 'review will be communicated to the site.', 'The primary efficacy endpoint os has been recognized as the gold standard for the', 'demonstration of superiority of a new antineoplastic therapy in randomized clinical studies.', 'For additional details about assessing efficacy endpoints using RECIST 1.1 and iRECIST,', 'see Appendix 6.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '52', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '4.2.1.1.1', 'RECIST 1.1', 'RECIST 1.1 will be used by the BICR when assessing images for efficacy measures and by', 'the local site when determining eligibility (Section 8.2.1.5). Although traditional RECIST 1.1', 'references a maximum of 5 target lesions in total and 2 per organ, this protocol has', 'implemented an adjustment to RECIST 1.1 to follow a maximum of 10 target lesions in total', 'and 5 per organ.', '4.2.1.1.2', 'Adjusted RECIST 1.1 for Immune-based Therapeutics iRECIST', 'RECIST 1.1 will be adapted to account for the unique tumor response characteristics seen', 'following treatment with pembrolizumab (Section 8.2.1.6). Immunotherapeutic agents such', 'as pembrolizumab may produce antitumor effects by potentiating endogenous cancer-specific', 'immune responses. The response patterns seen with such an approach may extend beyond the', 'typical time course of responses seen with cytotoxic agents, and patients treated with', 'pembrolizumab may manifest a clinical response after an initial increase in tumor burden or', 'even the appearance of new lesions. Thus, standard RECIST 1.1 may not fully capture the', 'treatment benefits from immunotherapeutic agents such as pembrolizumab. Based on an', 'analysis of participants with melanoma enrolled in KEYNOTE-001 (KN001), 7% of', 'evaluable participants experienced delayed or early tumor pseudoprogression. Of note,', 'participants who had PD by RECIST 1.1 but not by the immune-related response criteria', '[Wolchok, J. D., et al 2009] had longer OS than participants with PD by both criteria [Hodi,', 'F. S., et al 2014]. Additionally, the data suggest that RECIST 1.1 may underestimate the', 'benefit of pembrolizumab in approximately 15% of participants. These findings support the', 'need to apply an adjustment to RECIST 1.1 that takes into account the unique patterns of', 'atypical responses in immunotherapy and enables treatment beyond initial radiographic', 'progression, if the participant is clinically stable.', 'iRECIST assessment has been developed and published by the RECIST Working Group,', 'with input from leading experts from industry and academia, along with participation from', 'the United States Food and Drug Administration (FDA) and the European Medicines Agency', '(EMA) [Seymour, L., et al 2017]. The unidimensional measurement of target lesions,', 'qualitative assessment of nontarget lesions, and response categories are identical to RECIST', '1.1, until progression is seen by RECIST 1.1. However, if a participant is clinically stable,', 'additional imaging may be performed to confirm radiographic progression. iRECIST will be', 'used by investigators to assess tumor response and progression and make treatment decisions', 'as well as for exploratory efficacy analyses where specified.', '4.2.1.2', 'Safety Enppoints', 'Safety parameters commonly used for evaluating investigational systemic anticancer', 'treatments are included as safety endpoints including, but not limited to, the incidence of,', 'causality, and outcome of AEs/serious AEs (SAEs); and changes in vital signs and laboratory', 'values. Adverse events will be assessed as defined by the NCI Common Terminology', 'Criteria for Adverse Events (CTCAE), Version 4.0.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}